MoonLake Immunotherapeutics

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 22.6, 161, 435.98, 775.93 ], "ebit_estimate": [ -286.13, -316.78, -267.35, -117.34, 216.73 ], "ebitda_estimate": [ -311.32, -229.86, -302.86, -149.04, null ], "net_income_estimate": [ -283.4, -305.4, -264.62, -71.15, 207.36 ], "per_share_eps_estimate": [ -3.9, -3.71, -3.01, -1.33, 2.09 ], "eps_nri_estimate": [ -3.87, -3.65, -2.89, -1.33, 2.16 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -282.95, -320.34, -282.94, -88.65, 224.14 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -140.69, -203.2, -105.93, null, null ], "gross_margin_estimate": [ null, 81, 81, 85.5, 85.5 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 9.76 ], "long_term_growth_rate_mean": 6.34, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 6.34, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": -7.78, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, 0.11, null, 2.67, 20.97 ], "ebit_estimate": [ -68.38, -69.64, -70.52, -89.5, -77.3, -78.9, -75.6 ], "ebitda_estimate": [ -67.16, -70.18, -71.64, -103.17, null, null, null ], "net_income_estimate": [ -68.3, -69.37, -70.92, -75.5, -77, -78.5, -75.3 ], "per_share_eps_estimate": [ -0.95, -0.95, -0.93, -0.95, -1.02, -1.07, -0.89 ], "eps_nri_estimate": [ -0.94, -0.95, -0.93, -1.05, -1.02, -1.07, -0.89 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -67.83, -68.88, -70.49, -71, -72, -74, -76 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -117.28, -158.97, -243.07, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 6.34, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 6.34, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": -7.78, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }